Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281290 | 0.77 | FDPS (0.37) | FDPSGGPS1LMNAMMP1MMP2 | |
| SCHEMBL282438 | 0.77 | FDPS (0.37) | FDPSGGPS1LMNA | |
| SCHEMBL6051813 | 0.77 | FDPS (0.37) | FDPSGGPS1LMNAMMP1MMP2 | |
| Hydrochloric Acid SCHEMBL4158783 | 0.75 | FDPS (0.36) | FDPSGGPS1LMNA | |
| SCHEMBL2857624 | 0.75 | FDPS (0.39) | FDPSSMPD1GGPS1LMNA | |
| SCHEMBL2298232 | 0.75 | FDPS (0.36) | FDPSGGPS1LMNA | |
| SCHEMBL2857618 | 0.75 | GGPS1 (0.37) | FDPSGGPS1LMNAMMP1MMP2 | |
| SCHEMBL870763 | 0.75 | TSHR (0.39) | FDPSSMPD1LMNA | |
| SCHEMBL8643730 | 0.74 | FDPS (0.39) | FDPSSMPD1GGPS1LMNA | |
| SCHEMBL27587972 | 0.73 | FDPS (0.39) | FDPSGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899743-B2 | Substituted glycine derived FXIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3331872-B1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10336730-B2 | Substituted glycine derived FXIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3331872-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9643923-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2017-05-09 | — | — | US | disclosed |
| WO-2017023992-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-9376444-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150307450-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1607401-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | Metabasis Therapeutics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| US-6107284-A | Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal products and their intended use in anti-cancer treatments | PIERRE FABRE MEDICAMENT (FR) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | CUTA, MMP8, CLPP | FDPS 2463/4885SMPD1 662/4885GGPS1 2065/4885 |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | FDPS 187/4885SMPD1 655/4885GGPS1 1567/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | FDPS 134/4885SMPD1 365/4885GGPS1 668/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | FDPS 111/4885SMPD1 362/4885GGPS1 784/4885 |
| US-20150307450-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | FDPS 2029/4885SMPD1 1633/4885GGPS1 604/4885 |
| US-10336730-B2 | Substituted glycine derived FXIA inhibitors | F2, TFPI, TFPI2 | FDPS 1038/4885SMPD1 2415/4885GGPS1 1292/4885 |
| US-10899743-B2 | Substituted glycine derived FXIA inhibitors | F2, TFPI, TFPI2 | FDPS 1038/4885SMPD1 2415/4885GGPS1 1292/4885 |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | TFPI, TFPI2, F2 | FDPS 1053/4885SMPD1 2823/4885GGPS1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.